How were Liminal BioSciences' earnings last quarter?

Liminal BioSciences Inc. (NASDAQ:LMNL) released its quarterly earnings data on Monday, November, 15th. The company reported $27.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.80) by $30.20. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.02 million. Liminal BioSciences had a negative trailing twelve-month return on equity of 88.44% and a net margin of 248.35%.

When did Liminal BioSciences' stock split?

Liminal BioSciences's stock reverse split on the morning of Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Liminal BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liminal BioSciences investors own include ADMA Biologics (ADMA) , CNBX Pharmaceuticals (CNBX) , Gran Tierra Energy (GTE) , Pennsylvania Real Estate Investment Trust (PEI) , Aeterna Zentaris (AEZS) , American Cannabis (AMMJ) , Bionano Genomics (BNGO) , Bergio International (BRGO) , CBL & Associates Properties (CBL) and Auxly Cannabis Group (CBWTF) .

NASDAQ:LMNL

Liminal BioSciences (LMNL) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free LMNL Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $8.48
▼
$8.50
50-Day Range: $8.38
▼
$8.50
52-Week Range: $3.10
▼
$8.50

Volume: 5,000 shs
Average Volume: 63,470 shs
Market Capitalization: $26.35 million

P/E Ratio: 29.31
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Liminal BioSciences alerts:

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Liminal BioSciences Stock (NASDAQ:LMNL)

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Click here to see the details.

LMNL Stock News Headlines

September 26, 2023 | finance.yahoo.com

LIMINAL BIOSCIENCES ANNOUNCES COMPLETION OF THE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

September 19, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

September 19, 2023 | msn.com

Liminal BioSciences gets final order for the Structured Alpha takeover

September 19, 2023 | finance.yahoo.com

LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

September 15, 2023 | finance.yahoo.com

LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LP

September 12, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

September 12, 2023 | finance.yahoo.com

LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULAR

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

August 16, 2023 | msn.com

Liminal BioSciences shareholders to vote on takeover deal Sept. 15

August 16, 2023 | finance.yahoo.com

LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LP

August 8, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: Liminal BioSciences Reports Second Quarter Financial Results 2023

August 8, 2023 | finance.yahoo.com

Liminal BioSciences Reports Second Quarter Financial Results 2023

July 13, 2023 | prnewswire.com

Limina BioSciences annonce la conclusion d'un accord avec Structured Alpha LP

July 13, 2023 | finance.yahoo.com

Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder

July 12, 2023 | marketwatch.com

Liminal BioSciences Accepts $8.50 a Share Buyout Offer From Structured Alpha

July 12, 2023 | msn.com

LMNL Skyrockets on Acquisition by Structured Alpha

July 12, 2023 | benzinga.com

Liminal BioSciences Stock Gains0% Today - Here's Why?

July 12, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP

July 12, 2023 | msn.com

Liminal BioSciences stock rockets on take-private deal with a fund managed by Thomvest Asset Management

July 12, 2023 | finance.yahoo.com

Liminal BioSciences Announces Arrangement Agreement with Structured Alpha LP

June 5, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

June 5, 2023 | finance.yahoo.com

Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders

June 2, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: Liminal BioSciences Provides R&D Update

June 2, 2023 | finance.yahoo.com

Liminal BioSciences Provides R&D Update

May 9, 2023 | finanznachrichten.de

Liminal BioSciences Inc.: Liminal BioSciences Reports First Quarter Financial Results 2023

May 9, 2023 | msn.com

Liminal BioSciences reports results

See More Headlines

Receive LMNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/15/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LMNL
CUSIP: N/A
CIK: 1351172
Web: www.liminalbiosciences.com
Phone: 1-450-781-0115
Fax: 1-450-781-4477
Employees: 251
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.29
Trailing P/E Ratio: 29.31
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $380,000.00
Net Margins: 248.35%
Pretax Margin: -5,729.40%
Return on Equity: -88.44%
Return on Assets: -64.15%

Debt

Debt-to-Equity Ratio: 0.02
Current Ratio: 2.78
Quick Ratio: 2.78

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 85.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.97 per share
Price / Book: 0.95

Miscellaneous

Outstanding Shares: 3,100,000
Free Float: 3,036,000
Market Cap: $26.35 million
Optionable: Not Optionable
Beta: 1.03

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Bruce Pritchard BA (Age 49)
CA, FIOD, Chief Exec. Officer
Comp: $698.94k
Mr. Patrick Sartore (Age 48)
Pres
Comp: $613.82k
Dr. Gary J. Bridger Ph.D. (Age 60)
Interim Chief Scientific Officer & Non-Independent Director
Comp: $264.69k
Ms. Marie Iskra L.L.B. (Age 46)
Corp. Sec. & Gen. Counsel
Comp: $435.82k
Ms. N. Nicole Rusaw C.A. (Age 50)
C.P.A., CA, CPA, HBACC, Chief Financial Officer
Shrinal Inamdar
Mang. of Investor Relations & Communications
Dr. Steven J. Burton
Pres of Prometic Bioseparations Ltd

Key Competitors

View All Competitors

LMNL Stock Analysis - Frequently Asked Questions

How were Liminal BioSciences' earnings last quarter?: Liminal BioSciences Inc. (NASDAQ:LMNL) released its quarterly earnings data on Monday, November, 15th. The company reported $27.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.80) by $30.20. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.02 million. Liminal BioSciences had a negative trailing twelve-month return on equity of 88.44% and a net margin of 248.35%.
When did Liminal BioSciences' stock split?: Liminal BioSciences's stock reverse split on the morning of Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of Liminal BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Liminal BioSciences investors own include ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Aeterna Zentaris (AEZS), American Cannabis (AMMJ), Bionano Genomics (BNGO), Bergio International (BRGO), CBL & Associates Properties (CBL) and Auxly Cannabis Group (CBWTF).

This page (NASDAQ:LMNL) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Liminal BioSciences (LMNL) Stock Price, News & Analysis

About Liminal BioSciences Stock (NASDAQ:LMNL)

LMNL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

LMNL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info